"Stock crashed, founders are departing to start a new company, and the post-pandemic development has been disappointing, raising questions about its future innovation."

"Negative sentiment due to founders leaving, lack of stock movement despite strong cash reserves and late-stage drug pipeline, and questions about future catalysts."

"Co-founders Uğur Şahin and Özlem Türeci announced their departure, causing a 17% drop in stock value and raising significant concerns about the company's future and potential takeover."

"Founders resigned to pursue pure research, causing a 20% stock drop despite a strong pipeline."

"The co-founders, pivotal to the company's success and innovation, are leaving to start a new venture, causing a significant 23% stock drop and market uncertainty about its future direction."